Teeccino Is Ready for Explosive Growth
Teeccino, a coffee alternative, has achieved product-market fit and is looking for explosive growth in the coming years.
Teddy Lyons
Analyst Report: Upgrade for access 20/20 GeneSystems Makes Cancer Screening Affordable
20/20 GeneSystems offers an affordable test that screens for multiple types of cancers. But the market may not be ready for 20/20's solution.
- Details
- Company: 20/20 GeneSystems
- Security Type: Convertible Note
- Valuation: $58,400,000
- Min Investment: $500
- Platform: StartEngine
- Deadline: Dec 21, 2022
Teddy Lyons - November 9th, 2022
Blood Will Tell
Cancer is the most studied disease in the world. Just about everyone has been affected by it in one way or another. And when it comes to cancer treatment, the news is always the same — new experimental drugs, new trial therapies. Like you, I hope that we will have a cure for cancer one day. But right now, that day seems to be pretty far off.
In the meantime, what is the most effective way to address cancer? The answer is clear: early detection. When cancer is detected at Stage 1, survival rates increase substantially. (Most studies show at least five years of survival after early diagnosis.) However, the infrastructure in place for cancer detection is based on X-ray, magnetic resonance imaging, and other types of specialized technology. There is really no well-known alternative to these expensive, image-based tests.Â
Well, the company I am introducing today — 20/20 GeneSystems — offers a blood-based cancer detection test for just $189. 20/20’s OneTest is the cheapest cancer test on the market and utilizes a method called tumor antigen detection. Tumor antigen testing has been around for decades. It detects the presence of cancer-specific proteins in the body. 20/20 increases the accuracy of traditional antigen tests by using artificial intelligence (AI) and algorithms, and it can find multiple types of cancer: colon, lung, ovarian, prostate, liver, stomach, and pancreatic.
How? Well, since 2018, the company has gotten access to the records of more than 200,000 patients with known cancer outcomes. Once a OneTest sample is received, 20/20 uses machine learning algorithms based on these medical records to predict the likelihood of a patient having cancer. Currently, the company is targeting individual consumers and high-risk occupational groups (like firefighters).
Now that you know what 20/20 GeneSystems is all about, let’s dig deeper into the performance of the business.Â
Pay Annually - save 17%
save 17%
This content requires: Edge
Data-driven startup investment ratings, AI analyst reports, and portfolio company exit and failure tracking
$
30
/month
25
/annually
What's included
- Everything in Free plus
- Data-driven investment ratings and AI analyst reports
- Advanced company search table (with ratings and reports)
- Markets page filters and historical industry data
- Startup investment exit and failure tracker
- Startup Portfolio Tracking
- Follows
- Advanced Search Table
- Founder Profiles
- Trending Companies
- Fundraising Analytics
- News and Crowdopedia
Advanced Search table full access, including ratings and analyst reports.
Charts and trends of capital raised by platform, security type, industry, and more.
Unlock Ratings and AI analyst report filters in the Advanced Company Search.
Track IPOs, acquisitions, failures and other exits for companies in your portfolio.
